Literature DB >> 6229699

Modulation of cellular immune function by cyclophosphamide in children with minimal-change nephropathy.

J Feehally, T J Beattie, P E Brenchley, B M Coupes, I B Houston, N P Mallick, R J Postlethwaite.   

Abstract

Cyclophosphamide is widely used to induce a remission of minimal-change nephropathy, but concerns have been raised about whether its effects on cellular immunity persist after treatment is discontinued. We studied functional and numerical measures of cellular immunity in children who had minimal-change nephropathy with frequent steroid-responsive relapses and were receiving cyclophosphamide (2.5 mg per kilogram of body weight per day for eight weeks). Sequential studies during such treatment showed that cyclophosphamide caused lymphopenia, particularly among T helper cells, resulting in a significant fall in the immunoregulatory (helper/suppressor) cell ratio. This change persisted 1 to 3 months after cyclophosphamide was discontinued, but measures of immune function reverted to normal after 6 to 12 months. Children with minimal-change nephropathy in long-term remission had no difference in T-cell subpopulations, lymphocyte responses to mitogens, or suppressor-cell function that could be attributed to the disease itself or to the previous use of cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6229699     DOI: 10.1056/NEJM198402163100702

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  8 in total

1.  Focal glomerulosclerosis in children: an Argentinian experience.

Authors:  A Tufro-McReddie; E Alvarez; E Arrizurieta; H Repetto
Journal:  Pediatr Nephrol       Date:  1992-03       Impact factor: 3.714

Review 2.  The immune system in minimal change nephrotic syndrome.

Authors:  H W Schnaper
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

3.  Eight and 12 week courses of cyclophosphamide in nephrotic syndrome.

Authors:  N Ueda; K Kuno; S Ito
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

4.  Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Authors: 
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

5.  Cyclosporin A treatment in children with minimal change nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  J Brodehl; M Brandis; U Helmchen; P F Hoyer; R Burghard; J H Ehrich; R B Zimmerhackl; W Klein; K Wonigeit
Journal:  Klin Wochenschr       Date:  1988-11-15

6.  Impaired immunoglobulin G production in minimal change nephrotic syndrome in adults.

Authors:  H Yokoyama; H Kida; T Abe; Y Koshino; M Yoshimura; N Hattori
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

7.  Treatment of steroid-resistant post-transplant nephrotic syndrome with cyclophosphamide in a child with congenital nephrotic syndrome.

Authors:  J T Flynn; S L Schulman; J P deChadarevian; S P Dunn; B A Kaiser; M S Polinsky; H J Baluarte
Journal:  Pediatr Nephrol       Date:  1992-11       Impact factor: 3.714

8.  Lymphocytopenia as an independent predictor of early recurrence in breast cancer.

Authors:  C W Pattison; K L Woods; J M Morrison
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.